2. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV management: recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org
. Accessed March 10, 2020.
3. Weiss JJ, Brau N, Stivala A, et al. Adherence to medication for chronic hepatitis C-building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther 2009;30:14-27.
4. Gayam V, Tiongson B, Khalid M, et al. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study. Eur J Gastroenterol Hepatol 2018;30:1200-1207.
5. Mason K, Dodd Z, Guyton M, et al. Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy 2017;47:202-208.
6. National Viral Hepatitis Roundtable, Center for Health Law and Policy Innovation, Harvard Law School. Hepatitis C: the state of Medicaid access. https://stateofhepc.org
. Published October 2017. Accessed March 10, 2020.
7. Dimova RB, Zeremski M, Jacobson IM, et al. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013;56:806-816.
8. Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013;57(suppl 2):S80-S89.
9. Weiss JJ, Alcorn MC, Rabkin JG, et al. The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. J Hepatol 2012;56:503-504.
10. Weiss JJ, Aaronson C, Cervantes L, et al. A behavioral intervention improves the rate of hepatitis C treatment initiation among HIV/HCV coinfected patients: results of a randomized controlled trial. J Hepatol 2007;66(1 suppl):S490.
11. Balfour L, Tasca GA, Kowal J, et al. Development and validation of the HIV Medication Readiness Scale. Assessment 2007;14:408-416.
12. Fernández MI, Hosek S, Warren JC, et al. Development of an easy to use tool to assess HIV treatment readiness in adolescent clinical care settings. AIDS Care 2011;23:1492-1499.
13. Gebrekristos HT, Mlisana KP, Karim QA. Patients’ readiness to start highly active antiretroviral treatment for HIV. BMJ 2005;331:772-775.
14. Dupont SC, Fluker SA, Quairoli KM, et al. Improved hepatitis C cure cascade outcomes among urban baby boomers in the direct-acting antiviral era. Public Health Rep 2020;135:107-113.
15. Miller L, Fluker SA, Osborn M, et al. Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic. J Natl Med Assoc 2012;104:244-250.
16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
17. Beck KR, Kim NJ, Khalili M. Direct acting antivirals improve HCV treatment initiation and adherence among underserved African Americans. Ann Hepatol 2018;17:413-418.
18. Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int 2013;33:999-1007.
19. Lieveld FI, van Vlerken LG, Siersema PD, et al. Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Ann Hepatol 2013;12:380-391.
20. Evon DM, Esserman DA, Bonner JE, et al. Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence. J Viral Hepat 2013;20:536-549.
21. Bonner JE, Esserman DA, Golin CE, et al. Self-efficacy and adherence to antiviral treatment for chronic hepatitis C. J Clin Gastroenterol 2015;49:76-83.
22. Gowda C, Lott S, Grigorian M, et al. Absolute insurer denial of direct-acting antiviral therapy for hepatitis C: a national specialty pharmacy cohort study. Open Forum Infect Dis 2018;5:ofy076.